# CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME FOR THE PERIOD ENDED 28 FEBRUARY 2021

	2021 Current Quarter Ended 28-Feb RM'000	2020 Comparative Quarter Ended 29-Feb RM'000	2021 Cumulative Year To Date 28-Feb RM'000	2020 Cumulative Year To Date 29-Feb RM'000
Income				
Revenue	15,047	2,280	21,953	12,302
Cost of sales	(7,275)	(1,981)	(8,753)	(8,235)
Gross Profit	7,772	299	13,200	4,067
Other income	111	7	2,886	68
Total Income	15,157	2,287	24,839	12,370
Expenses				
Selling and distribution	(1)	(33)	(4)	(62)
Administrative and general expenses	47	(1,449)	(2,215)	(2,915)
Profit / (Loss) from Operations (EBITA)	7,929	(1,176)	13,867	1,158
Amortisation of Intangible Assets	(932)	(932)	(2,796)	(2,796)
Depreciation	(112)	(71)	(336)	(214)
Profit / (Loss) Before Interest, Taxes (EBIT), Impairment and ESOS Expenses	6,885	(2,179)	10,735	(1,852)
ESOS Expenses	(4,630)	_	(4,630)	
Profit / (Loss) Before Interest, Taxes and Impairement less ESOS Expenses	2,255	(2,179)	6,105	(1,852)
Impairment loss on trade receivables	-	(569)	-	(2,034)
Profit / (Loss) Before Interest and Taxes	2,255	(2,748)	6,105	(3,886)
Finance Cost	(22)	(20)	(67)	(57)
Profit / (Loss) before Tax	2,233	(2,768)	6,038	(3,943)
Profit / (Loss) before tax is stated after charging/(credi	ting):-			
Interest income	(16)	(27)	(17)	(27)
Impairment loss on trade receivables	-	569	-	2,034
Depreciation and amortisation	1,044	1,003	3,132	3,009
ESOS expenses	4,630	-	4,630	-
Foreign exchange (gain) / loss	(688)	(44)	234	(34)
Income tax expense	(120)	<u>.</u>	(120)	
•	<u> </u>	(0.700)		(2.0.42)
Profit / (Loss) for the period	2,113	(2,768)	5,918	(3,943)
Foreign currency translation	(739)	-	(174)	-
Total Comprehensive Profit / (Loss)	1,374	(2,768)	5,744	(3,943)
Attributable to :- Owners of the Company Non-Controlling Interests	2,113	(2,768)	5,918	(3,943)
	2,113	(2,768)	5,918	(3,943)
Total comprehensive profit / (loss) attributable to:- Owners of the Company Non-Controlling Interests	1,374 -	(2,768)	5,744	(3,943) -

#### Non-Controlling Interests

	1,374	(2,768)	5,744	(3,943)
Earnings / (Loss) per share - Basic (sen)	0.37	(0.60)	1.04	(0.85)
- Diluted (sen)	0.36	(0.60)	1.02	(0.85)

Note:

The Condensed Consolidated Statements of Comprehensive Income should be read in conjunction with the audited financial statements for the period ended 31 May 2020 and the accompanying explanatory notes attached to the interim financial statements.

# UCREST BERHAD

(Company No.: 420056-K)

# CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 28 FEBRUARY 2021

	As At 28 February 2021 RM'000	As At 31 May 2020 RM'000
ASSETS		
Non-Current Assets Property, Plant and Equipment Right-of-use Assets Intangible Assets Total Non-Current Assets	361 211 21,884 22,456	579 330 24,680 25,589
		20,000
Current Assets Trade Receivables Other Receivables Tax Recoverable Deposits, Cash and Bank Balances Total Current Assets	19,748 81 383 10,105 30,316	14,297 509 207 1,539 16,552
Total Assets	52,772	42,141
EQUITY AND LIABILITIES Capital and Reserves Share capital Reserves Total Equity	35,889 6,909 42,798	21,762 (2,892) 18,870
Non-Current Liabilities Trade and Other Payables Total Non-Current Liabilities	<u>217</u> 217	240 240
Current Liabilities Trade Payables Other Payables Leased Liabilities Bank Overdraft Total Current Liabilities Total Liabilities <b>Total Equity and Liabilities</b>	9,440 83 234 - 9,757 9,974 <b>52,772</b>	16,196 6,498 336 1 23,031 23,271 <b>42,141</b>
Net Assets Per Share Attributable to owners of the Company (Sen)	8	4

Note:

The Condensed Consolidated Statement of Financial Position should be read in conjunction with the audited financial statements for the year ended 31 May 2020 and the accompanying explanatory notes attached to the interim financial statements.

# UCREST BERHAD

(Company No.: 420056-K)

# CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE PERIOD ENDED 28 FEBRUARY 2021

		Foreign Currency			Equity Attributable	
	Share Capital RM'000	translation Reserve RM'000	ESOS Reserve RM'000	Accumulated Loss RM'000	to the Owners of the Company RM'000	Total Equity RM'000
Quarter ended 28 Februay 2021						
Balance as at 1 June 2020 (Audited), As previously stated	21,762	88	1,477	(4,457)	18,870	18,870
Issuance of shares						
- private placement	12,774	-	-	-	12,774	12,774
<ul> <li>pursuant to exercise of ESOS</li> </ul>	1,353	-	(573)	-	780	780
<ul> <li>share options granted under ESOS</li> </ul>	-	-	4,630	-	4,630	4,630
Profit/(loss) for the period	-	(174)	-	5,918	5,744	5,744
	21,763					
Comprehensive profit/(loss) for the period	14,127	(174)	4,057	5,918	23,928	23,928
Balance as at 28 February 2021 (Unaudited)	35,889	(86)	5,534	1,461	42,798	42,798

Note:

The condensed consolidated statement of changes in equity should be read in conjunction with the audited financial statements for the year ended 31 May 2020 and the accompanying notes attached to the interim financial statements.

# UCREST BERHAD

(Company No.: 420056-K)

# CONDENSED CONSOLIDATED CASH FLOW STATEMENT FOR THE PERIOD ENDED 28 FEBRUARY 2021

	9 Months to date ended 28/02/2021 RM'000	12 Months to date ended 31/05/2020 RM'000
CASH FLOWS FROM OPERATING ACTIVITIES		
Profit / (Loss) before tax	6,038	(22,990)
Adjustments for:		
Amortisation of intangible assets	2,796	3,748
Depreciation of property, plant and equipment	217	287
Depreciation of right-of-use asset	119	145
Impairment loss on intangible assets	-	3,279
Impairment loss on trade receivables	-	15,328
Reversal of impairment loss on trade receivables	(768)	-
Reversal of provision of project cost	(2,000)	-
ESOS expenses	-	1,477
Share-based payments expense	4,630	-
Finance costs	67	94
Interest income	(17)	(26)
Foreign exchange translation	(174)	423
Unrealised gain on foreign exchange translation	-	(467)
Operating profit before changes in working capital	10,908	1,298
Changes in working capital:-		
Inventories	-	-
Trade and other receivables	(4,255)	(9,897)
Trade and other payables	(11,193)	7,597
Cash used in operations Interest received	(4,540) 17	(1,002) 26
Tax paid	(296)	(170)
Net cash used in operating activities	(4,819)	(1,146)
Net cash used in operating activities	(4,019)	(1,140)
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of property, plant & equipment	-	(33)
Net cash used in investing activities	-	(33)
CASH FLOWS FROM FINANCING ACTIVITIES		
Proceed from issuance of share capital		
- private placement	12,774	-
<ul> <li>pursuant to exercise of ESOS</li> </ul>	780	-
Repayment of lease liability	(102)	(150)
Interest paid	(67)	(83)
Net cash generated from / (used in) financing activities	13,385	(233)
NET INCREASE / (DECREASE) IN CASH AND CASH EQUIVALENTS	8,566	(1,412)
CASH AND CASH EQUIVALENTS AT 01 JUNE	1,539	2,920
EFFECTS OF EXCHANGE RATE CHANGES	-	31
CASH AND CASH EQUIVALENTS AS AT END OF THE FINANCIAL PERIOD	10,105	1,539

# Cash and cash equivalents

Cash and cash equivalents included in the statements of cash flows comprise the following statements of financial position amounts:

Deposits	8,048	47
Cash and bank balances	2,057	1,492
	10,105	1,539

Note:

The condensed consolidated cash flow statement should be read in conjunction with the audited financial statements for the year ended 31 May 2020 and the accompanying notes attached to the interim financial statements.

(Company No.: 420056-K)

# SELECTED EXPLANATORY NOTES

## 1. Accounting Policies and Methods Of Computation

The current quarter financial report ended 28 February 2021 is unaudited and has been prepared in accordance with Malaysian Financial Reporting Standards ("MFRS") 134 "Interim Financial Reporting" and Paragraph 9.22 of the Listing Requirements of Bursa Malaysia Securities Berhad ("Bursa Securities") for the ACE Market.

The report should be read in conjunction with the audited financial statements of the Group for the financial year ended 31 May 2020. The explanatory notes attached to the quarterly financial report provide an explanation on events and transactions that are significant to an understanding of the changes in the financial position and performance of the Group since the financial year ended 31 May 2020.

The accounting policies and methods of computation adopted by the Group in the quarterly financial report are consistent with those adopted in the audited financial statements of the Group for the financial year ended 31 May 2020.

#### 2. Auditors' Report on Preceding Annual Financial Statements

The auditors' report on the audited financial statements for the year ended 31 May 2020 was not qualified.

### 3. Segmental Reporting

### **Geographical information**

	Individual Qu	Individual Quarter Ended		ual YTD
	28-Feb-21 RM'000	29-Feb-20 RM'000	28-Feb-21 RM'000	29-Feb-20 RM'000
Malaysia	74	-	208	188
China and other Asian countries	14,973	-	14,973	-
Russia	-	2,280	6,772	12,114
Group revenue	15,047	2,280	21,953	12,302

### 4. Unusual Items

During the quarter under review, there were no unusual items affecting assets, liabilities, equity, net income, or cash flows of the Group.

#### 5. Changes In Estimates Of Amount Reported Previously Affecting Current Interim Period

There are no changes in estimates of amount reported that will have a material effect in the current interim period.

### 6. Seasonality or Cyclicality

The operations of the Group are not subject to any seasonality or cyclicality factors.

### 7. Dividends Paid Or Proposed

Dividends were neither paid nor proposed during the current interim period.

## 8. Valuation of Property, Plant and Equipment

The Group has not carried out any valuation on its property, plant & equipment.

#### 9. Debts and Equity Securities

There were no issuances, cancellations, repurchases, resale and repayments of debt and equity securities.

# 10. Change In The Composition of The Group

There has been no change in the composition of the group for the quarter review.

# SELECTED EXPLANATORY NOTES

## **11. Discontinued Operation**

There were no discontinued operations within the activities of the Group for the quarter under review.

#### **12. Capital Commitments**

There were no capital commitments for the purchase of any property, plant and equipment or any other expenses that were not accounted for in the financial statements of the quarter under review.

#### 13. Changes In Contingent Liabilities & Assets

There are no material contingent liabilities as at the date of this report.

#### 14. Subsequent Events

There were no material events subsequent to the end of the reporting quarter that have not been reflected in the quarter under review.

### Additional Information As Per ACE Market Listing Requirement

#### **15. Review Of Performance**

During the current quarter under review, the Group recorded a net profit attributable to Owners of the Company of RM2,113 million.

### 16. Material Change In the Profit / (Loss) Before Taxation Compared To The Results of :-

	Immediate Preceding Quarter		Individual Quarter Ended		Individual YTD	
	28-Feb-21 RM'000	30-Nov-20 RM'000	28-Feb-21 RM'000	29-Feb-20 RM'000	28-Feb-21 RM'000	29-Feb-20 RM'000
P/(L)BITDA	7,929	3,680	7,929	(1,176)	13,867	1,158
Less : Amortisation of intangible assets	(932)	(932)	(932)	(932)	(2,796)	(2,796)
Less : Depreciation	(112)	(112)	(112)	(71)	(336)	(214)
Less : ESOS expenses	(4,630)	-	(4,630)	-	(4,630)	-
Less : Impairment los on trade receivables	-	-	-	(569)	-	(2,034)
Less : Finance cost	(22)	(23)	(22)	(20)	(67)	(57)
Profit / (Loss) before tax	2,233	2,613	2,233	(2,768)	6,038	(3,943)

The Group recorded profit before tax of RM 2,233 million in the current quarter, and profit before tax of RM 2,613 million in the immediate preceding quarter.

### **17. Commentary Of Prospects**

The Group has inked a deal to contract manufacture the Sputnik V vaccine with minimum commitment of 100 million doses and up to 1 billion doses for the first two years. The quantity on the third year will be adjusted depending on the market dynamic at that time. The deal is take or pay for the quantity of vaccines produced. Despite of the vaccination in some of the countries, the number of COVID-19 new cases globally continues to increase. Some countries are spiking up in the third wave and some have started the fourth wave. The vaccines in the market appear to be effective only for a few months and it is likely that 2 rounds of vaccines per year are needed. It looks like this business will be good for next few years.

iMedic continues to gain traction in the market. Due to the restriction of international and movement in most countries for the foreseeable future, the Group has realigned its resources to focus on China and other COVID-19 "safe" countries so that sales and marketing activities can progress as normal. The Group expects to make significant progress in these markets.

### 18. Profit Forecast

There was no profit forecast issued by the Group.

### 19. Taxation

The tax expenses for the 9 months period ending 28 February 2021 consist of the following :-

	RM'000
Current tax :	
Underprovision of tax expenses	(120)
	(120)

# SELECTED EXPLANATORY NOTES

## 20. Unquoted Investments / Properties

There were no purchase or sales of unquoted investments or properties during the current interim period under review.

#### 21. Purchase or Disposal of Quoted Securities

There were no purchase or disposal of quoted securities during the current interim period under review.

#### 22. Status of Corporate Proposal

The Company had at the Extraordinary General Meeting held on 22 January 2018 obtained the shareholders' approval for a private placement exercise to issue up to 106,901,642 new ordinary shares in the Company representing not more than twenty percent (20%) of the issued share capital of the company ("Private Placement").

35,600,000 new Ordinary Shares were issued pursuant to the Private Placement and were subsequently listed and quoted on the Ace Market of Bursa Malaysia Securities Berhad.

The details of the utilisation of proceeds from the Private Placement were as follows:-

Description	Proposed Utilisation (RM'000)	Actual Utilisation (RM'000)	Balance to be utilized (RM'000)
Payment for cost of sales	11,328	11,328	0
Payment of salaries	1,285	596	689
Payment of office rentals	161	83	78

The Proposed Private Placement is deemed completed on 17 December 2020.

#### 23. Group Borrowings and Debt Securities

There were no borrowings and debts securities for the financial quarter under review.

#### 24. Off Balance Sheet Financial Instruments

There were no off balance sheet financial instruments as at the date of this report.

#### 25. Material Litigation

There were no Material Litigation for the financial quarter under review.

#### 26. Realised and Unrealised Profits/Losses

On 25 March 2010, Bursa Securities issued a directive to all listed issuers pursuant to Rules 2.07 and 2.23 of Bursa Securities ACE Market Listing Requirements. The directive requires all listed issuers to disclose the breakdown of the unappropriated profits or accumulated losses as at the end of the reporting period, into realised and unrealised profits and losses.

On 20 December 2010, Bursa Securities further issued guidance on the disclose and the format period.

The breakdown of accumulated profit / (losses) of the Group as at the reporting date, into realised and unrealised losses, pursuant to the directive, is as follows:

	Gro	up
	<u>Unaudited</u> 28/02/2021 RM'000	<u>Audited</u> 31/05/2020 RM'000
Total accumulated profit / (losses) of UCrest Berhad and it's subsidiaries:		
- Realised	1,668	(4,501)
- Unrealised - in respect of other items of income and expense	(207)	44
Total Group accumulated profit as per consolidated accounts	1,461	(4,457)

The determination of realised and unrealised losses is based on the Guidedance of Special Matter No.1, Determination of Realised and Unrealised Profits or Losses in the Context of Disclosure Pursuant to Bursa Malaysia Securities Berhad Listing Requirements, issued by the Malaysian Institute of Accountants on 20 December 2010.

The disclosure of realised and unrealised losses above is solely for complying with the disclosure requirements stipulated in the directive of Bursa Malaysia and should not be applied for any other purposes.

# SELECTED EXPLANATORY NOTES

# 27. Dividends Payable

The Board of Directors does not recommend any interim dividends for the current quarter ended 28 February 2021.

# 28. Earnings / (Loss) Per Share

# (a) Basic

The basic earnings / (loss) per share for the quarter and cumulative year to date are computed as follow:

	Individual quarter ended		<u>Cumulat</u>	ive YTD
	<u>Unaudited</u> 28-Feb-21	Audited 29-Feb-20	<u>Unaudited</u> 28-Feb-21	<u>Audited</u> 29-Feb-20
Net profit / (loss) attributable to owners of the company (RM'000)	2,113	(2,768)	5,918	(3,943)
Weighted average number of ordinary shares in issue ('000)	566,927	464,033	566,927	464,033
Basic earnings / (loss) per share (sen)	0.37	(0.60)	1.04	(0.85)

# (b) Diluted

The diluted earning / (loss) per share for the quarter and cumulative year to date are computed as follow:

	Individual quarter ended		Cumulative YTD	
	<b>Unaudited</b>	<b>Audited</b>	<b>Unaudited</b>	<b>Audited</b>
	28-Feb-21	29-Feb-20	28-Feb-21	29-Feb-20
Net profit / (loss) attributable to owners of the company (RM'000)	2,113	(2,768)	5,918	(3,943)
Dilutive shares on option outstanding ('000)	584,651	464,033	582,821	464,033
Diluted earnings / (loss) per share (sen)	0.36	(0.60)	1.02	(0.85)